Monitoring for Extra-Intestinal Cancers in IBD
- ,
- S. Kane(corresponding author)
- ,
- Mayo Clinic Rochester, MN
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
Multiple studies have demonstrated an increased risk for extra-intestinal cancers in inflammatory bowel disease (IBD) patients, mainly from treatment modalities. Prominent cancers that are related to IBD treatment include the following: lymphoproliferative disorders associated with thiopurine use, hepatosplenic T cell lymphoma primarily in younger male patients on thiopurines and anti-tumor necrosis factor (TNF) agents, non-melanoma skin cancers in patients treated with thiopurines and anti-TNF agents, and melanomas in patients who are on monotherapy with anti-TNF agents. In addition, women with IBD may have higher rates of cervical dysplasia and cervical cancer. The focus of this review is to provide a comprehensive overview on extra-intestinal cancers in IBD patients and how to monitor for these malignancies.
Publication Information
Output type
Original language
English (US)Article number
42Journal (Volume, Issue Number)
Current Gastroenterology Reports (Volume 17, Issue 11)Publication milestones
- Published - 11/22/2015
Publication status
ISSN
1522-8037Publication IDs
- Scopus: 84941917561
- PubMed: 26364836
